

A PREDOMINANT ROLE OF AMINO GROUPS IN THE ANTIBACTERIAL ACTION OF AMINOGLYCOSIDES: SYNTHESIS OF HEXA- AND HEPTADEOXYKANAMYCIN DERIVATIVES*

Sir:

As reported in a previous paper¹⁾ we have studied polydeoxy derivatives of kanamycins and found that 5,3',4',4'',6''-pentadeoxykanamycin B having only one hydroxyl group at C-2'' is still active in inhibiting both the growth of bacteria and protein synthesis on pseudomonas ribosomes. Its 1-*N*-[(*S*)-4-amino-2-hydroxybutyl] derivative had strong activity against Gram-positive and -negative bacteria including pseudomonas.¹⁾ In order to understand the role of the 2''-hydroxyl group in the antibacterial activity of polydeoxykanamycins, we have synthesized 5,2',3',4',4'',6''-hexadeoxykanamycin (1), 5,2',3',4',2'',4'',6''-heptadeoxykanamycin (2), 5,2',3',4',4'',6''-hexadeoxyamikacin (3) and 5,2',3',4',2'',4'',6''-heptadeoxyamikacin (4), starting from 3',4'-dideoxykanamycin B (5).** In this paper, we report on the synthesis of these deoxy derivatives and their antibacterial activity.

Compound 1 was synthesized by successive deoxygenation of 5 at C-5, C-4'' and C-6'', followed by deamination at C-2'. Compound 2 was obtained by deoxygenation of 1. 6'-*N*-Cbz-3',4'-dideoxykanamycin B²⁾ (6) prepared from 5 was acylated with an equimolar amount of *tert*-butyl *S*-4,6-dimethylpyrimid-2-ylthiocarbonate (Kokusan Chemical Works, Tokyo) in a mixture (10:10:1) of pyridine, water and triethylamine at room temperature for 21 hours to afford 2'-*N*-Boc-6'-*N*-Cbz-3',4'-dideoxykanamycin B (7) in 28% yield. From this reaction mixture, 42% of 6 was recovered. Compound 7 was treated with 4.5 equivalents of benzyl *S*-4,6-dimethylpyrimid-2-ylthiocarbonate in a mixture of methanol and



















triethylamine at room temperature for 19 hours to give 2'-*N*-Boc-1,3,6',3''-tetra-*N*-Cbz-3',4'-dideoxykanamycin B (8) in 81% yield. Acetonization of 8 with 2,2-dimethoxypropane in *N,N*-dimethylformamide in the presence of *p*-toluenesulfonic acid at room temperature for 20 hours followed by benzylation of the 2''-hydroxyl group with benzoyl chloride in pyridine at room temperature for 3 hours gave the 4'',6''-*O*-isopropylidene-2''-benzoate 9 in 86% yield. The 5-deoxygenation³⁾ of 9 was accomplished by chlorination with sulfur chloride (3 equiv.) in pyridine under ice-cooling for 1 hour followed by reduction with tributylstannane in toluene under an argon atmosphere in the presence of α,α' -azobisisobutyronitrile at 100°C for 2 hours affording 2''-*O*-benzoyl-2'-*N*-Boc-1,3,6',3''-tetra-*N*-Cbz-4'',6''-*O*-isopropylidene-5,3',4'-trideoxykanamycin B (10) in 60% yield, mp 148~152°C, $[\alpha]_D^{25} +129^\circ$ (*c* 1, CHCl₃).

Removal of the *O*-isopropylidene group in 10 with a mixture (3:3:1) of acetic acid, methanol and water at 50°C for 2 hours afforded 2''-*O*-benzoyl-2'-*N*-Boc-1,3,6',3''-tetra-*N*-Cbz-5,3',4'-trideoxykanamycin B (11) in 94% yield. The 4'',6''-dideoxygenation⁴⁾ of 11 was accomplished by mesylation with methanesulfonyl chloride (4 equiv.) in pyridine at room temperature for 3 hours affording the dimesylate 12 (96% yield), iodination with an excess of sodium iodide in *N,N*-dimethylformamide at 90°C for 16 hours (85% yield), catalytic hydrogenation with Raney-Ni (R-200, Nikko Scientific & Chemical Ind., Tokyo) in dioxane in a Parr apparatus (3.5 kg/cm²) for 25 hours and re-*N*-benzyloxycarbonylation (71% yield) to give 2''-*O*-benzoyl-2'-*N*-Boc-1,3,6',3''-tetra-*N*-Cbz-5,3',4',4'',6''-pentadeoxykanamycin B (13), mp 162~165°C, $[\alpha]_D^{25} +106^\circ$ (*c* 1, CHCl₃).

The 2''-*O*-benzoyl and 2'-*N*-Boc groups of 13 were removed by successive treatments with 5% sodium methylate in methanol at room temperature for 2.5 hours and with 90% trifluoroacetic acid for 1 hour to afford 1,3,6',3''-tetra-*N*-Cbz-5,3',4',4'',6''-pentadeoxykanamycin B (14) in 59% yield, mp 189~194°C (decomp.), $[\alpha]_D^{25} +109^\circ$ (*c* 1, DMF). Deamination of 14 at the 2'-position was carried out by the method of BARTON⁵⁾ as follows. *N*-Formylation of 14 with *p*-nitrophenyl formate in *N,N*-dimethylformamide at room temperature for 3 hours followed by *O*-acetylation with acetic anhydride in pyridine in the presence of 4-dimethylaminopyridine at room temperature

* Dedicated to Professor EDGAR LEDERER on the occasion of his 75th birthday.

** Compounds 1~4 and 7 were purified by column chromatography on Amberlite CG-50 (NH₄⁺) eluted with diluted ammonia. Compounds, 9, 10, 13~19 and 21~23 were purified by column or thin-layer chromatography on silica gel developed with mixtures of chloroform and methanol. Reasonable NMR spectral data were obtained for all compounds cited in this report.



Abbreviations

Cbz: Benzylloxycarbonyl

Boc: *tert*-Butoxycarbonyl

Bz: Benzoyl

for 2 hours gave the 2'-*N*-formyl-2''-*O*-acetate **15** in 72% yield. Compound **15** was heated with *p*-toluenesulfonyl chloride (1.5 equiv.) in pyridine⁶⁾ at 80°C for 4 hours to yield the 2'-isonitrile **16** in 71% yield, mp 167~171°C (decomp.), $[\alpha]_D^{25} +76^\circ$ (*c* 0.5, DMF). Reduction of **16** with tributylstannane in toluene in the presence of α, α' -azobisisobutyronitrile at 120°C for 8 hours (**17**, 30% yield) followed by removal of the *O*-acetyl

group with 16% ammonia in methanol at room temperature for 3 hours (78% yield) gave 1,3,6', 3''-tetra-*N*-Cbz-5,2', 3', 4', 4'', 6''-hexadecykanamycin (**18**), mp 176~181°C, $[\alpha]_D^{25} +55^\circ$ (*c* 0.5, CH₃OH). Catalytic hydrogenation of **18** under a hydrogen stream with 5% Pd on charcoal in a mixture (1: 500: 500) of acetic acid, methanol and water at room temperature for 13 hours afforded **1** as the carbonate (C₁₈H₃₆N₄O₅·H₂CO₃·H₂O) in

Table 1. Minimum inhibitory concentrations ($\mu\text{g/ml}$) on Mueller-Hinton agar plates.

Test organism	Kanamycin (KM)	Hexa-deoxy KM (1)	Hepta-deoxy KM (2)	Amikacin (AM)	Hexa-deoxy AM (3)	Hepta-deoxy AM (4)
<i>Staphylococcus aureus</i> 209P	0.78	1.56	12.5	0.78	0.78	6.25
<i>S. aureus</i> Smith	0.39	0.78	6.25	0.39	1.56	3.13
<i>S. aureus</i> ApO1 ^{a)}	12.5	3.13	>100	1.56	3.13	25
<i>S. epidermidis</i> 109 ^{a)}	50	3.13	25	3.13	1.56	25
<i>Micrococcus flavus</i> FDA16	12.5	12.5	100	6.25	6.25	50
<i>M. luteus</i> PCI1001	12.5	12.5	50	3.13	6.25	50
<i>Bacillus anthracis</i>	0.78	1.56	12.5	0.78	1.56	3.13
<i>B. subtilis</i> PCI219	0.39	0.78	6.25	0.39	0.78	3.13
<i>B. subtilis</i> NRRL B-558	0.39	0.78	6.25	0.39	0.78	6.25
<i>B. cereus</i> ATCC10702	3.13	6.25	50	6.25	6.25	25
<i>Corynebacterium bovis</i> 1810	6.25	6.25	50	1.56	6.25	50
<i>Mycobacterium smegmatis</i> ATCC607	0.78	0.78	6.25	0.78	1.56	6.25
<i>Escherichia coli</i> NIHJ	0.78	3.13	12.5	1.56	1.56	3.13
<i>E. coli</i> K12	0.78	1.56	12.5	0.39	0.78	6.25
<i>E. coli</i> K12 R5 ^{b)}	>100	>100	>100	100	100	>100
<i>E. coli</i> K12 R388	0.78	1.56	6.25	0.39	0.78	3.13
<i>E. coli</i> K12 JSR11-2 ^{c)}	>100	25	12.5	1.56	1.56	3.13
<i>E. coli</i> K12 ML 1629 ^{c)}	>100	25	25	1.56	1.56	6.25
<i>E. coli</i> K12 ML1630	>100	25	50	3.13	3.13	12.5
<i>E. coli</i> K12 ML1410	3.13	3.13	25	1.56	3.13	12.5
<i>E. coli</i> K12 ML1410 R81 ^{e)}	>100	25	50	1.56	3.13	12.5
<i>E. coli</i> K12 LA290 R55 ^{d)}	50	100	100	1.56	1.56	6.25
<i>E. coli</i> K12 LA290 R56	6.25	12.5	12.5	0.78	1.56	6.25
<i>E. coli</i> K12 LA290 R64	6.25	25	50	1.56	3.13	6.25
<i>E. coli</i> W677	0.78	1.56	12.5	0.78	0.78	6.25
<i>E. coli</i> JR66/W677 ^{d, e)}	>100	>100	>100	3.13	3.13	12.5
<i>E. coli</i> K12 C600 R135 ^{f)}	0.78	1.56	12.5	0.78	1.56	12.5
<i>E. coli</i> JR225 ^{f)}	1.56	1.56	25	0.78	0.78	6.25
<i>Klebsiella pneumoniae</i> PCI602	1.56	1.56	12.5	0.78	1.56	6.25
<i>K. pneumoniae</i> 22#3038 ^{d, e)}	>100	>100	>100	3.13	3.13	25
<i>Shigella dysenteriae</i> JS11910	6.25	6.25	50	3.13	6.25	25
<i>S. flexneri</i> 4b JS11811	12.5	6.25	25	3.13	6.25	25
<i>S. sonnei</i> JS11746	3.13	3.13	25	3.13	3.13	25
<i>Salmonella typhi</i> T-63	0.39	0.78	12.5	0.39	0.78	6.25
<i>S. enteritidis</i> 1891	3.13	1.56	50	1.56	3.13	25
<i>Proteus vulgaris</i> OX19	0.78	1.56	12.5	1.56	0.78	6.25
<i>P. rettgeri</i> GN311	0.39	0.78	6.25	0.39	1.56	12.5
<i>P. rettgeri</i> GN466	0.78	1.56	3.13	0.78	1.56	1.56
<i>P. inconstans</i> Pv16 ^{g)}	3.13	12.5	50	1.56	3.13	12.5
<i>P. inconstans</i> 2991 ^{g)}	12.5	50	>100	1.56	6.25	100
<i>Serratia marcescens</i>	1.56	6.25	50	1.56	6.25	25
<i>Serratia</i> sp. SOU	>100	>100	>100	25	50	>100
<i>Serratia</i> sp. 4	25	25	>100	3.13	12.5	>100
<i>Pseudomonas aeruginosa</i> A3	6.25	3.13	12.5	<0.20	0.78	12.5
<i>P. aeruginosa</i> No. 12	25	50	>100	3.13	25	>100
<i>P. aeruginosa</i> H9 ^{e)}	>100	100	>100	6.25	50	>100
<i>P. aeruginosa</i> H11	100	>100	>100	12.5	100	>100
<i>P. aeruginosa</i> TI-13 ^{e)}	50	50	100	3.13	12.5	>100
<i>P. aeruginosa</i> GN315 ^{b)}	>100	>100	>100	25	>100	>100
<i>P. aeruginosa</i> 99 ^{f)}	>100	>100	>100	6.25	50	>100
<i>P. aeruginosa</i> B-13 ^{c, e)}	>100	>100	>100	6.25	50	>100
<i>P. aeruginosa</i> 21-75 ^{h)}	>100	>100	>100	12.5	100	>100
<i>P. aeruginosa</i> PST1 ^{f)}	>100	>100	>100	12.5	50	>100
<i>P. aeruginosa</i> ROS134/PU21 ^{f)}	>100	>100	>100	100	>100	>100
<i>P. aeruginosa</i> K-Ps102 ^{l)}	>100	>100	>100	6.25	50	>100
<i>P. maltophilia</i> GN907 ^{l)}	>100	>100	>100	>100	>100	>100

Resistance mechanisms^{g)} a) AAD (4'), b) AAC (6'), c) APH (3')-I, d) AAD (2''), e) APH (3')-II, f) AAC (3), g) AAC (2'), h) APH (3')-III, l) permeability.

59% yield, mp 191~196°C (decomp.), $[\alpha]_D^{25} +103^\circ$ (c 1, H₂O), SIMS m/z 389 (MH⁺), TLC (silica gel) 1-butanol - ethanol - chloroform - 17% ammonia, 4: 5: 2: 5 (solvent A): Rf 0.47, chloroform - methanol - concd. ammonia - water, 1: 4: 2: 1 (solvent B): Rf 0.78.

Preferential *N*-protection⁷⁾ of **1** by chelate formation with zinc diacetate dihydrate (4 equiv.) in 90% dimethyl sulfoxide at room temperature for 24 hours and acylation with benzyl *S*-4, 6-dimethylpyrimid-2-ylthiocarbonate (4 equiv.) at 50°C for 18 hours yielded 3,6',3''-tri-*N*-Cbz-5,2',3',4',4'',6''-hexadeoxykanamycin (**19**) in 62% yield. The 1-amino group of **19** was acylated with ethyl trifluoroacetate in methanol in the presence of triethylamine at room temperature for 23 hours to yield the *N*-trifluoroacetate **20** in 83% yield, mp 183~187°C (decomp.), $[\alpha]_D^{25} +51^\circ$ (c 0.2, CH₃OH). The deoxygenation⁸⁾ of the 2''-hydroxyl group in **20** was carried out by successive treatments with trifluoromethanesulfonic anhydride (2 equiv.) in pyridine in the presence of 4-dimethylaminopyridine (1 equiv.) at room temperature for 4 hours (**21**, 74% yield), followed by reaction with sodium thiophenolate in *N,N*-dimethylformamide at room temperature for 6 hours (**22**, 84% yield), reduction with Raney-Ni in ethanol at 80°C for 30 minutes and re-*N*-benzyloxycarbonylation (94% yield) to give 3,6',3''-tri-*N*-Cbz-1-*N*-trifluoroacetyl-5,2',3', 4',2'',4'',6''-heptadeoxykanamycin (**23**). The *N*-trifluoroacetyl group in **23** was removed by treatment with 16% ammonia in methanol at room temperature for 15 hours yielding 3,6', 3''-tri-*N*-Cbz-5, 2', 3', 4', 2'', 4'', 6''-heptadeoxykanamycin (**24**) in 97% yield. Removal of the *N*-Cbz groups in **24** by catalytic hydrogenation under a hydrogen stream with 5% Pd on charcoal in a mixture (1: 150: 150) of acetic acid, methanol and water gave **2** as the carbonate (C₁₈H₃₆N₄O₄ · H₂CO₃ · H₂O) in 78% yield, mp 193~197°C (decomp.), $[\alpha]_D^{25} +98^\circ$ (c 0.1, H₂O), SIMS m/z 373 (MH⁺), TLC (silica gel) solvent A: Rf 0.53, solvent B: Rf 0.81.

The 1-amino group of **19** was acylated with the *N*-hydroxysuccinimide ester of *N*-Cbz-(*S*)-4-amino-2-hydroxybutyric acid in dimethyl sulfoxide in the presence of triethylamine at room temperature for 4 hours and the Cbz groups of the acylated product were removed by catalytic hydrogenation with 5% Pd on charcoal to yield **3** as the carbonate (C₂₂H₄₃N₅O₇ · H₂CO₃ · 2H₂O)

in 51% yield, mp 157~162°C (decomp.), $[\alpha]_D^{25} +61^\circ$ (c 1, H₂O), SIMS m/z 490 (MH⁺), TLC (silica gel) solvent A: Rf 0.31, solvent B: Rf 0.46.

The 1-*N*-acylation of **24** with the *N*-hydroxysuccinimide ester of *N*-Cbz-(*S*)-4-amino-2-hydroxybutyric acid in dimethyl sulfoxide in the presence of triethylamine at room temperature for 5 hours followed by catalytic hydrogenation with 5% Pd on charcoal afforded **4** as the carbonate (C₂₂H₄₃-N₅O₆ · H₂CO₃ · H₂O) in 63% yield, mp 147~152°C, $[\alpha]_D^{25} +54^\circ$ (c 0.2, H₂O), SIMS m/z 474 (MH⁺), TLC (silica gel) solvent A: Rf 0.38, solvent B: Rf 0.49.

The minimum inhibitory concentration of compounds **1**~**4** on a Mueller-Hinton agar plate are shown in Table 1 in comparison with those of kanamycin and amikacin. Although compound **2** having no hydroxyl group is weakly active, **1** having only one hydroxyl group at C-2'' is very active against Gram-positive and -negative bacteria except pseudomonas and some resistant bacteria⁹⁾ producing AAC (6') and AAD (2''). Compound **3**, the 1-*N*-[(*S*)-4-amino-2-hydroxybutyryl] derivative of **1**, shows strong activity, but is slightly less than amikacin. Thus, it can be concluded that the amino groups of the kanamycin antibiotics play a predominant role in the antibacterial activity,¹⁰⁾ and the 2''-hydroxyl group and the (*S*)-4-amino-2-hydroxybutyryl moiety on the 1-amino group markedly augment the activity.

HAMA O UMEZAWA
HIROYUKI IWASAWA
DAISHIRO IKEDA
SHINICHI KONDO

Institute of Microbial Chemistry
14-23, 3-Chome, Kamiosaki,
Shinagawa-ku, Tokyo 141,
Japan

(Received May 4, 1983)

References

- 1) UMEZAWA, H.; T. MIYASAKA, H. IWASAWA, D. IKEDA & S. KONDO: Chemical modification 5,3',4'-trideoxykanamycin B. *J. Antibiotics* 34: 1635~1640, 1981
- 2) UMEZAWA, H.; Y. NISHIMURA, T. TSUCHIYA & S. UMEZAWA: Syntheses of 6'-*N*-methylkanamycin and 3',4'-dideoxy-6'-*N*-methylkanamycin B active against resistant strains having 6'-*N*-

- acetylating enzymes. *J. Antibiotics* 25: 743~745, 1972
- 3) SUAMI, T.; S. NISHIYAMA, Y. ISHIKAWA & E. UMEMURA: Modification of aminocyclitol antibiotics. 6. Preparation of 5-deoxykanamycin B. *Bull. Chem. Soc. Jpn.* 51: 2354~2357, 1978
 - 4) MIYASAKA, T.; D. IKEDA, S. KONDO & H. UMEZAWA: Syntheses and properties of the 6''-deoxy or 4'',6''-dideoxy derivatives of the kanamycin antibiotics. *J. Antibiotics* 33: 527~532, 1980
 - 5) BARTON, D. H. R.; G. BRINGMANN & W. B. MOTHERWELL: Reactions of relevance to the chemistry of aminoglycoside antibiotics. 15. The selective modification of neamine by radical-induced deamination. *J. Chem. Soc., Perkin Trans. 1*, 1980: 2665~2669, 1980
 - 6) HERTLER, W. R. & E. J. COREY: A novel preparation of isonitriles. *J. Org. Chem.* 23: 1221~1222, 1958
 - 7) TSUCHIYA, T.; Y. TAKAGI & S. UMEZAWA: 1-*N*-Acylation of aminocyclitol antibiotics *via* zinc chelation and resiospecific *N*-trifluoroacetylation. *Tetrahedron Lett.* 1979: 4951~4954, 1979
 - 8) HASKELL, T.H.; P.W.K. WOO & D.R. WATSON: Synthesis of deoxy sugar. Deoxygenation of an alcohol utilizing a facile nucleophilic displacement step. *J. Org. Chem.* 42: 1302~1305, 1977
 - 9) UMEZAWA, H. & S. KONDO: Mechanisms of resistance to aminoglycoside antibiotics. *In Handbook of Experimental Pharmacology*. Vol. 62. Aminoglycoside Antibiotics. *ed.*, H. UMEZAWA & I. R. HOOPER, pp. 267~292, Springer-Verlag, Berlin, Heidelberg, New York, 1982
 - 10) UMEZAWA, H.: Deoxyaminoglycosides active against resistant strains. *In Drug Resistance in Bacteria. Genetics, Biochemistry, and Molecular Biology.* *ed.*, S. MITSUHASHI, pp. 245~260, Japan Scientific Societies Press, Tokyo, 1982